Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer (NJLCG1402) - Biweekly nab-PTX for pretreated NSCLC patients (NJLCG1402)

orth Japan Lung Cancer Study Group (NJLCG)0 个研究点目标入组 42 人开始时间: 2014年8月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Previous treatment with paclitaxel 2) Grade 2 or higher peripheral neuropathy 3) Active double cancer 4) Symptomatic brain metastases 5) Pleural and peritoneal effusion likely to require surgical intervention, or pericardial effusion 6) Active infectious disease 7) Severe concurrent disease (intestinal paralysis, intestinal obstraction, poorly controlled diabetes, heart failure, renal failure, hepatic failure, active gastrointestinal ulceration, cardiac infarction within 6 months before enrollment, and grade 3 or higher angina so on) 8) Radiographically confirmed interstitial pneumonitis or pulmonary fibrosis. 9) Patient with autoimmune disease requiring immunosuppressive drugs 10) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 11) Uncontrolled psychiatric disease 12) Patient are treated with steroid continuously 13) History of severe drug allergies. 14) Physician concludes that the patient's participation in this trial is inappropriate.

发起方

orth Japan Lung Cancer Study Group (NJLCG)